In the preceding three months, 10 analysts have released ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE), presenting a wide array of perspectives from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts have recently evaluated Ultragenyx Pharmaceutical and provided 12-month price targets. The average target is $104.8, accompanied by a high estimate of $140.00 and a low estimate of $48.00. This current average has increased by 0.96% from the previous average price target of $103.80.

Investigating Analyst Ratings: An Elaborate Study

In examining recent analyst actions, we gain insights into how financial experts perceive Ultragenyx Pharmaceutical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ultragenyx Pharmaceutical's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Ultragenyx Pharmaceutical analyst ratings.

Discovering Ultragenyx Pharmaceutical: A Closer Look

A Deep Dive into Ultragenyx Pharmaceutical's Financials

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Revenue Growth: Ultragenyx Pharmaceutical's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 29.42%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -80.9%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Ultragenyx Pharmaceutical's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -44.3%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Ultragenyx Pharmaceutical's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -8.77%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Ultragenyx Pharmaceutical's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.16.

Analyst Ratings: What Are They?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.